This site is intended for health professionals only
Thursday 23 May 2019
Share |

New diabetes drug recommended

Merck & Co's Januvia recommended by the CHMP

Sitagliptin (Januvia), a new drug for the treatment of diabetes, has received a positive opinion from the CHMP and the EMEA, and could get full approval from the EMEA as soon as April.

This drug is the first in a new class of drugs called dipeptidyl peptidase-4 inhibitors. The FDA gave sitagliptin the green light in October 2006 as monotherapy and as add-on therapy to either metformin or thiazolidinediones to improve blood glucose control in patients with type 2 diabetes, when diet and exercise are not enough.

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine